BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+64.22%Price chart
Aug 26Aug 31Sep 3Sep 14Sep 17Sep 23Sep 28Oct 1
Key dataOct 1, 2026
Open$0.05
From 52W high−97.38%
Volume220560.00
Market cap$2.31M
P/E (TTM)—
P/S (TTM)3.1x
Div yield—
Key dataOct 1, 2026
Open
$0.05
From 52W high
−97.38%
Volume
220560.00
Market cap
$2.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
23.6
MomentumView details →
1D Return
+64.22%
YTD Return
−97.19%
SummaryUpdated Jun 1, 2026
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a commercial-stage biopharmaceutical company founded in 2017 and headquartered in New Haven, Connecticut. The company went public in March 2018 and specializes in developing treatments for neurological and psychiatric conditions using artificial intelligence and machine learning approaches. BioXcel's flagship product, IGALMI, received FDA approval for treating acute agitation associated with schizophrenia and bipolar disorders, marking the company's transition from a pure development-stage entity to a commercial operation.
Similar companies
Latest newsMore news →
BioXcel Therapeutics entered into a super-priority senior secured priming debtor-in-possession credit agreement providing up to $77.25 million in aggregate principal, including $19 million new money loans and $58.25 million roll-up loans, with an initial draw of $9.5 million.49d agoTeva Pharmaceutical Industries has made a bid to acquire certain assets of BioXcel Therapeutics, including the product Igalmi and a potential at-home agitation treatment, to expand its neuroscience portfolio.50d agoBioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking horse bidder in a court-supervised 363 auction process.53d ago